thalidomide has been researched along with Ache in 40 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Excerpt | Relevance | Reference |
---|---|---|
"Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate-to-severe psoriasis." | 9.24 | The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). ( Bewley, A; Day, RM; Goncalves, J; Gooderham, M; Green, L; Khanskaya, I; Piguet, V; Reich, K; Shah, K; Soung, J; Zhang, Z, 2017) |
" The effects of apremilast, an oral phosphodiesterase inhibitor, on pruritus, skin discomfort/pain, and patient global assessment of psoriasis disease activity (PgAPDA) were assessed in moderate/severe chronic plaque psoriasis patients in the phase 3 ESTEEM trials." | 9.22 | Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. ( Chen, R; Day, RM; Foley, P; Girolomoni, G; Goncalves, J; Mrowietz, U; Sobell, JM; Toth, D; Yosipovitch, G, 2016) |
"Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 9.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
"For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP)." | 9.14 | Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010) |
"Good response to combined pamidronate and thalidomide therapy can be expected in at least 50% of patients with treatment-resistant multiple myeloma with advanced osteolytic lesions." | 9.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
"This report-the second of a series on codeine and its alternates for pain and cough relief-contains a detailed evaluation of experimental and clinical data on newer substances having analgesic properties comparable to and in approximately the same range as those of codeine." | 8.74 | Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief. ( Eddy, NB; Friebel, H; Hahn, KJ; Halbach, H, 1969) |
"The aim of this study was to assess psychological/psychiatric problems and quality of life (QOL) in patients with thalidomide embryopathy (TE), with a specific focus on pain, including pain severity and the effects of coping strategies for pain." | 7.96 | Quality of life and pain in patients with thalidomide embryopathy in Japan. ( Hinoshita, F; Imai, K; Nakano, Y; Otomo, K; Sone, H, 2020) |
"Targeting of peripheral TRPA1 and central TRPV4 may be required to attenuate pain associated with CIPN elicited by thalidomide and related drugs." | 7.96 | Oxidative stress mediates thalidomide-induced pain by targeting peripheral TRPA1 and central TRPV4. ( Coppi, E; De Logu, F; De Siena, G; Geppetti, P; Landini, L; Li Puma, S; Marini, M; Marone, IM; Materazzi, S; Nassini, R; Padilha Dalenogare, D; Souza Monteiro de Araujo, D; Titiz, M; Trevisan, G, 2020) |
"These results suggest that thalidomide can efficiently alleviate bone cancer pain and it may be a useful alternative or adjunct therapy for bone cancer pain." | 7.76 | Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model. ( Gu, X; Ma, Z; Mei, F; Ren, B; Zhang, J; Zhang, R; Zheng, Y, 2010) |
"In an open study, 17 patients (16 women, 1 man) with refractory or severe rheumatoid arthritis were treated with thalidomide." | 7.67 | Treatment of refractory rheumatoid arthritis--the thalidomide experience. ( Gutiérrez-Montes, O; Gutiérrez-Rodríguez, O; Starusta-Bacal, P, 1989) |
"Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 6.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
" Phase 2 dosing was determined to be bortezomib 1." | 6.75 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010) |
"At diagnosis, although bone resorption markers were increased in more than 40% of the patients, only NTX (P = 0." | 6.72 | First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. ( Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2006) |
"Thalidomide was introduced as a sedative and antiemetic agent to the European market in the late 1950s." | 6.42 | [Novel potential uses of thalidomide in the management of pain? A review of the literature]. ( Bruera, E; Peuckmann, V; Strumpf, M; Zenz, M, 2003) |
"During maintenance medication at the fourth and eighth weekend, the two doses (50 and 25 mg/d) of thalidomide were equivalent in reducing the incidence of ulcers, ulcer number, and ulcer pain, respectively (all p > 0." | 5.51 | A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis. ( Deng, Y; Du, G; Pan, L; Tang, G; Wang, Y; Wei, W; Yao, H, 2022) |
" Pearson's correlation coefficients assessed relationships between efficacy endpoints (oral ulcer count, oral ulcer pain, Behçet's Syndrome Activity Scale (BSAS), Behçet's Disease Current Activity Form (BDCAF)) and QoL endpoints for apremilast at Week 12." | 5.51 | Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. ( Chen, M; Cheng, S; Hatemi, G; Kim, D; Mahr, A; McCue, S; Melikoğlu, M; Paris, M; Takeno, M; Yazici, Y, 2022) |
"Thalidomide has been shown to selectively inhibit TNF-alpha production." | 5.31 | Analgesic effect of thalidomide on inflammatory pain. ( Cunha, FQ; Ferreira, SH; Ribeiro, RA; Vale, ML, 2000) |
"Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate-to-severe psoriasis." | 5.24 | The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). ( Bewley, A; Day, RM; Goncalves, J; Gooderham, M; Green, L; Khanskaya, I; Piguet, V; Reich, K; Shah, K; Soung, J; Zhang, Z, 2017) |
" The effects of apremilast, an oral phosphodiesterase inhibitor, on pruritus, skin discomfort/pain, and patient global assessment of psoriasis disease activity (PgAPDA) were assessed in moderate/severe chronic plaque psoriasis patients in the phase 3 ESTEEM trials." | 5.22 | Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. ( Chen, R; Day, RM; Foley, P; Girolomoni, G; Goncalves, J; Mrowietz, U; Sobell, JM; Toth, D; Yosipovitch, G, 2016) |
"Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 5.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
"For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP)." | 5.14 | Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010) |
"Good response to combined pamidronate and thalidomide therapy can be expected in at least 50% of patients with treatment-resistant multiple myeloma with advanced osteolytic lesions." | 5.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
"Thalidomide and bortezomib are remarkably efficacious in the treatment of multiple myeloma." | 4.85 | Multiple myeloma, painful neuropathy, acupuncture? ( Chang, DZ; Chiang, J; Delasalle, K; Fang, W; Forman, A; Garcia, MK; Guo, Y; Lu, J; Romaguera, J; Wang, M; Yi, Q; Zhou, Y, 2009) |
"Dramatic relief of pain and life-altering changes in quality of life in some patients treated with immunomodulators such as thalidomide compel us to look more closely at unconventional mechanisms that may be involved in propagation of persistent pain." | 4.84 | Does thalidomide have an analgesic effect? Current status and future directions. ( Goli, V, 2007) |
"This report-the second of a series on codeine and its alternates for pain and cough relief-contains a detailed evaluation of experimental and clinical data on newer substances having analgesic properties comparable to and in approximately the same range as those of codeine." | 4.74 | Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief. ( Eddy, NB; Friebel, H; Hahn, KJ; Halbach, H, 1969) |
"As individuals with thalidomide embryopathy now reaching their 60's they undergo long-term sequelae of their prenatal damage and experience a wide range of secondary health problems, in particular chronic musculoskeletal pain, movement restrictions, and mental disorders." | 4.12 | Health-related quality of life after 50 years in individuals with thalidomide embryopathy: Evidence from a German cross-sectional survey. ( Alayli, A; Albus, C; Lüngen, M; Niecke, A; Peters, KM; Pfaff, H; Samel, C, 2022) |
"Targeting of peripheral TRPA1 and central TRPV4 may be required to attenuate pain associated with CIPN elicited by thalidomide and related drugs." | 3.96 | Oxidative stress mediates thalidomide-induced pain by targeting peripheral TRPA1 and central TRPV4. ( Coppi, E; De Logu, F; De Siena, G; Geppetti, P; Landini, L; Li Puma, S; Marini, M; Marone, IM; Materazzi, S; Nassini, R; Padilha Dalenogare, D; Souza Monteiro de Araujo, D; Titiz, M; Trevisan, G, 2020) |
"The aim of this study was to assess psychological/psychiatric problems and quality of life (QOL) in patients with thalidomide embryopathy (TE), with a specific focus on pain, including pain severity and the effects of coping strategies for pain." | 3.96 | Quality of life and pain in patients with thalidomide embryopathy in Japan. ( Hinoshita, F; Imai, K; Nakano, Y; Otomo, K; Sone, H, 2020) |
"Morphine is a μ-opioid analgesic drug which is used in the treatment and management of chronic pain." | 3.85 | Thalidomide attenuates the development and expression of antinociceptive tolerance to μ-opioid agonist morphine through l-arginine-iNOS and nitric oxide pathway. ( Dehpour, AR; Ejtemaei-Mehr, S; Hassanipour, M; Khan, MI; Moghaddaskho, F; Momeny, M; Mumtaz, F; Ostadhadi, S, 2017) |
"These results suggest that thalidomide can efficiently alleviate bone cancer pain and it may be a useful alternative or adjunct therapy for bone cancer pain." | 3.76 | Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model. ( Gu, X; Ma, Z; Mei, F; Ren, B; Zhang, J; Zhang, R; Zheng, Y, 2010) |
"In a series of 12 patients suffering from an HIV infection, including 9 with confirmed AIDS, who complained about pharyngeal pain in a fixed site, having a progressive intensity and not relieved by antalgics and the specific treatments that were prescribed empirically, and for whom etiological investigation yielded negative results, Thalidomide proved to be the only effective means of healing the exulcerated, nail-mark lesions or the ulcerated, budding, neoplastic-like lesions, and of completely suppressing pain." | 3.68 | [Mouth and pharyngeal hyperalgesic syndromes in AIDS]. ( Barry, B; Depondt, J; Gehanno, P; Gorin, I; Guedon, C; Leport, C; Poignonec, S, 1990) |
"In an open study, 17 patients (16 women, 1 man) with refractory or severe rheumatoid arthritis were treated with thalidomide." | 3.67 | Treatment of refractory rheumatoid arthritis--the thalidomide experience. ( Gutiérrez-Montes, O; Gutiérrez-Rodríguez, O; Starusta-Bacal, P, 1989) |
"Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 2.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
" Phase 2 dosing was determined to be bortezomib 1." | 2.75 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010) |
"At diagnosis, although bone resorption markers were increased in more than 40% of the patients, only NTX (P = 0." | 2.72 | First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. ( Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2006) |
"Thalidomide was introduced as a sedative and antiemetic agent to the European market in the late 1950s." | 2.42 | [Novel potential uses of thalidomide in the management of pain? A review of the literature]. ( Bruera, E; Peuckmann, V; Strumpf, M; Zenz, M, 2003) |
"Thalidomide has multiple actions, including anti-inflammatory and anti-angiogenic ones." | 2.42 | [Thalidomide--new prospective therapy in oncology]. ( Pałgan, I; Pałgan, K, 2003) |
"Propranolol has anti-inflammatory effects that contribute to its antinociceptive action in the TMJ of females." | 1.48 | Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action. ( Dias, EV; Parada, CA; Sartori, CR; Tambeli, CH; Teixeira, JM; Zanelatto, FB, 2018) |
"Since then, the patient has had two recurrences, coinciding with the reduction of thalidomide dosages, which were controlled by increasing the dose of the immunomodulator." | 1.48 | A Dramatic Case of Odynophagia. ( Diniz-Freitas, M; Diz, P; García-Caballero, L; Limeres, J; Seoane, J; Sopeña, B, 2018) |
"Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life." | 1.48 | Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. ( Greenberg, JD; Guo, N; Holmgren, SH; Karki, C; Lebwohl, M; Mason, M; Strober, B, 2018) |
"Multiple myeloma is an uncommon haematological cancer of plasma cells." | 1.48 | Multiple myeloma: Updated approach to management in 2018. ( Tomlinson, R, 2018) |
"Kaposiform hemangioendothelioma is a rare vascular tumor of childhood that is locally aggressive but has little metastatic potential and by itself is not known to be lethal." | 1.35 | Kaposiform hemangioendothelioma in multiple spinal levels without skin changes. ( Bradeen, HA; Kalof, AN; Lisle, JW, 2009) |
"Five patients complained of paresthesias and leg cramps." | 1.35 | Thalidomide and sensory neurotoxicity: a neurophysiological study. ( Arienti, S; Doria, A; Ermani, M; Rondinone, R; Zara, G, 2008) |
"Thalidomide has been shown to selectively inhibit TNF-alpha production." | 1.31 | Analgesic effect of thalidomide on inflammatory pain. ( Cunha, FQ; Ferreira, SH; Ribeiro, RA; Vale, ML, 2000) |
"In experiment 1, rats with the neuritis but not those with the myositis developed neuropathic pain symptoms." | 1.31 | A neuroimmune interaction in painful peripheral neuropathy. ( Bennett, GJ, 2000) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (10.00) | 18.7374 |
1990's | 2 (5.00) | 18.2507 |
2000's | 11 (27.50) | 29.6817 |
2010's | 18 (45.00) | 24.3611 |
2020's | 5 (12.50) | 2.80 |
Authors | Studies |
---|---|
da Silva, YK | 1 |
Augusto, CV | 1 |
de Castro Barbosa, ML | 1 |
de Albuquerque Melo, GM | 1 |
de Queiroz, AC | 1 |
de Lima Matos Freire Dias, T | 1 |
Júnior, WB | 1 |
Barreiro, EJ | 2 |
Lima, LM | 2 |
Alexandre-Moreira, MS | 1 |
Hernández, P | 1 |
Cabrera, M | 1 |
Lavaggi, ML | 1 |
Celano, L | 1 |
Tiscornia, I | 1 |
Rodrigues da Costa, T | 1 |
Thomson, L | 1 |
Bollati-Fogolín, M | 1 |
Miranda, AL | 1 |
González, M | 1 |
Cerecetto, H | 1 |
Deng, Y | 1 |
Wei, W | 1 |
Wang, Y | 1 |
Pan, L | 1 |
Du, G | 1 |
Yao, H | 1 |
Tang, G | 1 |
Niecke, A | 1 |
Peters, KM | 1 |
Alayli, A | 1 |
Lüngen, M | 1 |
Pfaff, H | 1 |
Albus, C | 1 |
Samel, C | 1 |
Hatemi, G | 1 |
Mahr, A | 1 |
Takeno, M | 1 |
Kim, D | 1 |
Melikoğlu, M | 1 |
Cheng, S | 1 |
McCue, S | 1 |
Paris, M | 1 |
Chen, M | 1 |
Yazici, Y | 1 |
Imai, K | 1 |
Sone, H | 1 |
Otomo, K | 1 |
Nakano, Y | 1 |
Hinoshita, F | 1 |
De Logu, F | 1 |
Trevisan, G | 1 |
Marone, IM | 1 |
Coppi, E | 1 |
Padilha Dalenogare, D | 1 |
Titiz, M | 1 |
Marini, M | 1 |
Landini, L | 1 |
Souza Monteiro de Araujo, D | 1 |
Li Puma, S | 1 |
Materazzi, S | 1 |
De Siena, G | 1 |
Geppetti, P | 1 |
Nassini, R | 1 |
Strober, B | 1 |
Karki, C | 1 |
Mason, M | 1 |
Guo, N | 1 |
Holmgren, SH | 1 |
Greenberg, JD | 1 |
Lebwohl, M | 1 |
Sopeña, B | 1 |
Limeres, J | 1 |
García-Caballero, L | 1 |
Diniz-Freitas, M | 1 |
Seoane, J | 1 |
Diz, P | 1 |
Zanelatto, FB | 1 |
Dias, EV | 1 |
Teixeira, JM | 1 |
Sartori, CR | 1 |
Parada, CA | 1 |
Tambeli, CH | 1 |
Chen, Y | 1 |
Luo, D | 1 |
Cai, JF | 1 |
Lin, CH | 1 |
Shen, Y | 1 |
Zou, J | 1 |
Guan, JL | 1 |
Tomlinson, R | 1 |
Yordanova, A | 1 |
Hose, D | 1 |
Neben, K | 1 |
Witzens-Harig, M | 1 |
Gütgemann, I | 1 |
Raab, MS | 1 |
Moehler, T | 1 |
Goldschmidt, H | 1 |
Schmidt-Wolf, IG | 1 |
Vozella, F | 1 |
Latagliata, R | 1 |
Carmosino, I | 1 |
Volpicelli, P | 1 |
Montagna, C | 1 |
Romano, A | 1 |
Roberto, A | 1 |
Finsinger, P | 1 |
Mancini, M | 1 |
Breccia, M | 1 |
Oliva, E | 2 |
Song, T | 1 |
Ma, X | 1 |
Gu, K | 1 |
Yang, Y | 1 |
Yang, L | 1 |
Ma, P | 1 |
Wang, W | 1 |
Zhao, J | 1 |
Yan, R | 1 |
Guan, J | 1 |
Wang, C | 1 |
Qi, Y | 1 |
Ya, J | 1 |
Sobell, JM | 1 |
Foley, P | 1 |
Toth, D | 1 |
Mrowietz, U | 1 |
Girolomoni, G | 1 |
Goncalves, J | 2 |
Day, RM | 2 |
Chen, R | 1 |
Yosipovitch, G | 1 |
Reich, K | 1 |
Gooderham, M | 1 |
Green, L | 1 |
Bewley, A | 1 |
Zhang, Z | 1 |
Khanskaya, I | 1 |
Shah, K | 1 |
Piguet, V | 1 |
Soung, J | 1 |
Popat, R | 1 |
Brown, SR | 1 |
Flanagan, L | 1 |
Hall, A | 1 |
Gregory, W | 1 |
Kishore, B | 1 |
Streetly, M | 1 |
Oakervee, H | 1 |
Yong, K | 1 |
Cook, G | 1 |
Low, E | 1 |
Cavenagh, J | 1 |
Khan, MI | 1 |
Ostadhadi, S | 1 |
Mumtaz, F | 1 |
Momeny, M | 1 |
Moghaddaskho, F | 1 |
Hassanipour, M | 1 |
Ejtemaei-Mehr, S | 1 |
Dehpour, AR | 1 |
Lisle, JW | 1 |
Bradeen, HA | 1 |
Kalof, AN | 1 |
Zhou, Y | 1 |
Garcia, MK | 1 |
Chang, DZ | 1 |
Chiang, J | 1 |
Lu, J | 1 |
Yi, Q | 1 |
Romaguera, J | 1 |
Delasalle, K | 1 |
Guo, Y | 1 |
Forman, A | 1 |
Fang, W | 1 |
Wang, M | 1 |
Richardson, PG | 1 |
Weller, E | 1 |
Lonial, S | 1 |
Jakubowiak, AJ | 1 |
Jagannath, S | 1 |
Raje, NS | 1 |
Avigan, DE | 1 |
Xie, W | 1 |
Ghobrial, IM | 1 |
Schlossman, RL | 1 |
Mazumder, A | 1 |
Munshi, NC | 1 |
Vesole, DH | 1 |
Joyce, R | 1 |
Kaufman, JL | 1 |
Doss, D | 1 |
Warren, DL | 1 |
Lunde, LE | 1 |
Kaster, S | 1 |
Delaney, C | 1 |
Hideshima, T | 1 |
Mitsiades, CS | 1 |
Knight, R | 1 |
Esseltine, DL | 1 |
Anderson, KC | 1 |
Wijermans, P | 1 |
Schaafsma, M | 1 |
Termorshuizen, F | 1 |
Ammerlaan, R | 1 |
Wittebol, S | 1 |
Sinnige, H | 1 |
Zweegman, S | 1 |
van Marwijk Kooy, M | 1 |
van der Griend, R | 1 |
Lokhorst, H | 1 |
Sonneveld, P | 1 |
Gu, X | 1 |
Zheng, Y | 1 |
Ren, B | 1 |
Zhang, R | 1 |
Mei, F | 1 |
Zhang, J | 1 |
Ma, Z | 1 |
O'Carroll, A | 1 |
O'Reilly, F | 1 |
Whitford, DL | 1 |
Peuckmann, V | 1 |
Strumpf, M | 1 |
Zenz, M | 1 |
Bruera, E | 1 |
HARRIS, SC | 1 |
ALLGOOD, JP | 1 |
Pałgan, K | 1 |
Pałgan, I | 1 |
DiNino, KC | 1 |
Tosi, P | 1 |
Zamagni, E | 1 |
Cellini, C | 1 |
Parente, R | 1 |
Cangini, D | 1 |
Tacchetti, P | 1 |
Perrone, G | 1 |
Ceccolini, M | 1 |
Boni, P | 1 |
Tura, S | 1 |
Baccarani, M | 1 |
Cavo, M | 1 |
Goli, V | 1 |
Zara, G | 1 |
Ermani, M | 1 |
Rondinone, R | 1 |
Arienti, S | 1 |
Doria, A | 1 |
MacPhail, L | 1 |
Ribeiro, RA | 1 |
Vale, ML | 1 |
Ferreira, SH | 1 |
Cunha, FQ | 1 |
Bennett, GJ | 1 |
Ciepłuch, H | 1 |
Baran, W | 1 |
Hellmann, A | 1 |
Gehanno, P | 1 |
Barry, B | 1 |
Depondt, J | 1 |
Guedon, C | 1 |
Poignonec, S | 1 |
Leport, C | 1 |
Gorin, I | 1 |
Gutiérrez-Rodríguez, O | 1 |
Starusta-Bacal, P | 1 |
Gutiérrez-Montes, O | 1 |
Eddy, NB | 1 |
Friebel, H | 1 |
Hahn, KJ | 1 |
Halbach, H | 1 |
Belda, W | 1 |
Manzoli, S | 1 |
Jordy, CF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease[NCT02307513] | Phase 3 | 207 participants (Actual) | Interventional | 2014-12-30 | Completed | ||
Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery[NCT04421209] | Phase 2 | 0 participants (Actual) | Interventional | 2020-12-31 | Withdrawn (stopped due to No funding source) | ||
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis[NCT01690299] | Phase 3 | 250 participants (Actual) | Interventional | 2012-10-01 | Completed | ||
A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients[NCT02145715] | Phase 1/Phase 2 | 54 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-03-21 | Recruiting | ||
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma[NCT02103335] | Phase 1 | 38 participants (Actual) | Interventional | 2014-06-05 | Completed | ||
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance[NCT01647165] | Phase 2 | 0 participants (Actual) | Interventional | 2012-07-11 | Withdrawn | ||
A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Recruiting | ||
An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma[NCT00378105] | Phase 1/Phase 2 | 68 participants (Actual) | Interventional | 2006-09-30 | Active, not recruiting | ||
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603] | 100 participants (Anticipated) | Observational | 2021-11-30 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The number of oral ulcers that was counted for the analysis of the primary endpoint included current and recurrent ulcers at each time point; a single oral ulcer could be recounted multiple times if it persisted or recurred at subsequent visits. (NCT02307513)
Timeframe: Oral ulcers were assessed at weeks 0 (baseline), 1, 2, 4, 6, 8, 10, and 12 during the placebo-controlled period.
Intervention | Ulcers*days (Least Squares Mean) |
---|---|
Placebo | 222.14 |
Apremilast 30 mg BID | 129.54 |
The Behçet's Disease Quality of Life questionnaire was developed to measure the influence of BD on a particpant's life. It consists of 30 self-completed itemized questions that measure disease-related restrictions on the participant's activities and their emotional response to these restrictions. The total score is the sum of all 30 items (each yes scores 1 and each no scores 0), with 0 representing no influence of Behçet's disease on a participant's quality of life and 30 representing the most severe influence. A negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Placebo | -0.5 |
Apremilast 30 mg BID | -3.5 |
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI consists of 12 questions regarding disease manifestations over the previous 4 weeks, including oral and genital disease activity, as well as other manifestations of BD involving the skin, joints, GI tract, eyes, nervous system, and vascular system. The BDCAI score is the sum score of 12 items and ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Placebo | -0.4 |
Apremilast 30 mg BID | -0.9 |
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Clinician's Overall Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Placebo | -0.7 |
Apremilast 30 mg BID | -1.6 |
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Patient's Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Placebo | -0.7 |
Apremilast 30 mg BID | -1.7 |
The Behçet's Syndrome Activity Score (BSAS) contains 10 questions that assess the number of new oral and genital ulcers and skin lesions, GI, CNS, vascular, and ocular involvement, and the participant's current level of discomfort. The Behçet's Syndrome Activity Score ranges from 0 to 100, with a higher score indicating a higher level of disease activity. A negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Placebo | -5.41 |
Apremilast 30 mg BID | -17.35 |
Pain of genital ulcers was measured using a 100 mm visual analog scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | mm (Least Squares Mean) |
---|---|
Placebo | -24.5 |
Apremilast 30 mg BID | -30.0 |
"Pain of oral ulcers was measured using a 100 mm VAS scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded.~A negative change from baseline indicates improvement." (NCT02307513)
Timeframe: Baseline to week 12
Intervention | mm (Least Squares Mean) |
---|---|
Placebo | -15.9 |
Apremilast 30 mg BID | -40.7 |
"BD-related skin lesions (including acne-like lesions, folliculitis, and erythema nodosum) were evaluated according to the Static Physician's Global Assessment as follows:~Score 0 = clear skin. Score 1 = mild in severity with the presence of 1 to 10 lesions (papules, pustules, cysts) or nodules at any anatomical site.~Score 2 = Moderate severity; presence of 11 to 20 nodules or lesions (papules, pustules, cysts) at any anatomical site.~Score 3 = Severe; presence of > 20 nodules or lesions (papules, pustules, cysts) at any anatomical site.~The total sore was calculated as the sum of the acne-like lesions, folliculitis, and erythema nodosum scores, and therefore ranges from 0 to 9, where a higher score indicates a higher level of activity. A negative change from baseline indicates improvement." (NCT02307513)
Timeframe: Baseline to week 12
Intervention | scores on a scale (Least Squares Mean) |
---|---|
Placebo | -0.8 |
Apremilast 30 mg BID | -0.9 |
Number of oral ulcers reported at the time of the first loss of complete response, ie, at the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | oral ulcers (Least Squares Mean) |
---|---|
Placebo | 1.5 |
Apremilast 30 mg BID | 1.1 |
Participants who were oral ulcer-free by week 6 and remained oral ulcer-free for at least 6 consecutive weeks during the 12-week placebo-controlled treatment phase. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | Percentage of participants (Number) |
---|---|
Placebo | 4.9 |
Apremilast 30 mg BID | 29.8 |
A genital ulcer complete response at week 12 was defined as participants who were genital ulcer-free at week 12. (NCT02307513)
Timeframe: Week 12
Intervention | Percentage of participants (Number) |
---|---|
Placebo | 41.2 |
Apremilast 30 mg BID | 70.6 |
A complete response at week 12 was defined as participants who were oral ulcer free at week 12. (NCT02307513)
Timeframe: Week 12
Intervention | Percentage of participants (Number) |
---|---|
Placebo | 22.3 |
Apremilast 30 mg BID | 52.9 |
The definition includes participants who remained oral ulcer-free through week 12 after achieving a complete response (oral ulcer-free) prior to week 12. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | Percentage of participants (Number) |
---|---|
Placebo | 13.2 |
Apremilast 30 mg BID | 31.3 |
Time to oral ulcer resolution (defined as oral ulcer-free) was the time between the first dose date and the date when a complete response was achieved for the first time during the placebo-controlled treatment phase. For participants who did not achieve complete response or discontinued treatment before a complete response was achieved during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment date during the placebo-controlled treatment phase or the first dose date if there were no postbaseline ulcer assessments. Median and 95% confidence interval was based on Kaplan-Meier estimates. (NCT02307513)
Timeframe: Baseline to week 12
Intervention | Weeks (Median) |
---|---|
Placebo | 8.1 |
Apremilast 30 mg BID | 2.1 |
Time to recurrence of oral ulcers following the loss of complete response (oral ulcer-free) was defined as the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase. For participants who did not have oral ulcer recurrence or discontinued treatment before any oral ulcer recurrence during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment during placebo-controlled treatment phase; For participants without any oral ulcer assessment following the first complete response, time to event was censored to the first complete response date. (NCT02307513)
Timeframe: Baseline through week 12
Intervention | Weeks (Median) |
---|---|
Placebo | 2.3 |
Apremilast 30 mg BID | 4.6 |
"The apremilast-exposure period started on the date of the first dose of apremilast (week 0 for participants assigned to apremilast or week 12 for participants who were originally assigned to placebo and switched to apremilast at week 12) and ended 28 days after last dose in the active treatment phase.~An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. An SAE is any AE that resulted in death; was life-threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. The investigator assessed the severity of each event according to the grading scale:~Mild: asymptomatic or mild symptoms; Moderate: symptoms causing moderate discomfort, local or noninvasive intervention indicated; Severe: symptoms causing severe discomfort or pain, requiring medical/surgical intervention (NCT02307513)
Timeframe: From first dose of apremilast (week 0 for those assigned to apremilast or week 12 for those assigned to placebo) up to 28 days after last dose; up to 56 weeks and 68 weeks in each arm respectively.
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Any TEAE | Any Drug-related TEAE | Any Severe TEAE | Any Serious TEAE | Any TEAE Leading to Drug Interruption | Any TEAE Leading to Drug Withdrawal | Any TEAE Leading to Death | |
Apremilast/Apremilast | 90 | 64 | 17 | 10 | 17 | 12 | 0 |
Placebo/Apremilast | 70 | 29 | 4 | 7 | 10 | 3 | 0 |
"A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE (SAE) is any AE that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale:~Mild: asymptomatic or with mild symptoms; Moderate: symptoms causing moderate discomfort and local or noninvasive intervention is indicated; Severe: symptoms causing severe discomfort or pain, symptoms requiring medical/surgical intervention." (NCT02307513)
Timeframe: From first dose of study drug in the placebo-controlled phase to the first dose of apremilast in the active treatment phase (12 weeks) or up to 28 days after last dose for participants who did not receive study drug at week 12, whichever was earlier.
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Any TEAE | Any Drug-related TEAE | Any Severe TEAE | Any Serious TEAE | Any TEAE Leading to Drug Interruption | Any TEAE Leading to Drug Withdrawal | Any TEAE Leading to Death | |
Apremilast 30 mg BID | 82 | 60 | 6 | 3 | 9 | 3 | 0 |
Placebo | 74 | 37 | 6 | 4 | 6 | 5 | 0 |
"DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from Very Much (score 3) to Not at All or Not relevant (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if No, then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being A lot, A little, or Not at all (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best." (NCT01690299)
Timeframe: Baseline to Week 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | -3.9 |
Apremilast 30mg Plus Placebo Injection | -8.4 |
Etanercept 50mg Plus Placebo Tablet | -7.8 |
The SF-36 is a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Scores from the 8 scales were transformed to the norm-based scores using weights from U.S. general population to have a mean of 50 and variance = 10, with higher scores indicating better health. From these 8 scale, two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS), both having the same mean of 50 and variance = 10 as noted for the individual scales for the U.S. general population, and with higher scores indicating better health. For MCS, change from baseline was calculated, where change = visit value - baseline value. (NCT01690299)
Timeframe: Baseline to Week 16
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 2.6 |
Apremilast Plus Placebo Injection | 3.5 |
Etanercept Plus Placebo Tablets | 4.8 |
"BSA is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or handprint including the fingers), which equates to approximately 1% of total body surface area. BSA percent change from baseline was determined at each visit of the study, and is calculated as 100*(post-baseline BSA - baseline BSA) / baseline BSA." (NCT01690299)
Timeframe: Baseline to Week 16
Intervention | percent change (Least Squares Mean) |
---|---|
Placebo | -16.3 |
Apremilast Plus Placebo Injection | -47.7 |
Etanercept Plus Placebo Tablets | -56.1 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing. (NCT01690299)
Timeframe: Baseline to Week 16
Intervention | percentage of participants (Number) |
---|---|
Placebo | 33.3 |
Apremilast Plus Placebo Injection | 62.7 |
Etanercept Plus Placebo Tablet | 83.1 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing. (NCT01690299)
Timeframe: Baseline and Week 16
Intervention | percentage of participants (Number) |
---|---|
Placebo | 11.9 |
Etanercept 50mg Plus Placebo Tablet | 48.2 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing. (NCT01690299)
Timeframe: Baseline to Week 16
Intervention | Percentage of participants (Number) |
---|---|
Placebo | 11.9 |
Apremilast Plus Placebo Injection | 39.8 |
The Lattice System Physician's Global Assessment is a global assessment performed by the investigator of psoriasis severity. Integrating ranges of BSA involvement with assessments of overall plaque severity (using a 4 point scale from none to marked for the signs of plaque elevation, erythema and scale), the LS-PGA produces an overall assessment of psoriasis severity on an 8-point scale, ranging from clear to very severe. To determine the final score, the lattice portion is governed by the BSA and among the plaque qualities, weights plaque elevation as most important, erythema next, and scale least. (NCT01690299)
Timeframe: Baseline to Week 16
Intervention | percentage of participants (Number) |
---|---|
Placebo | 6.0 |
Apremilast Plus Placebo Injection | 24.1 |
Etanercept Plus Placebo Tablets | 22.9 |
The sPGA is an assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall severity, the Investigator should factor in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the severity of each sign is averaged across all areas of involvement, including cleared lesions. In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score. (NCT01690299)
Timeframe: Baseline and Week 16
Intervention | percentage of participants (Number) |
---|---|
Placebo | 3.6 |
Apremilast Plus Placebo Injection | 21.7 |
Etanercept Plus Placebo Tablet | 28.9 |
A TEAE in the apremilast-exposure phase is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes listed above. (NCT01690299)
Timeframe: From the first dose of apremilast (either Week 0 for participants originally randomized to apremilast or Week 16 for those originally randomized to placebo or etanercept who were switched to apremilast at week 16) until 28 days after last apremilast dose
Intervention | participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Any TEAE | Any Drug-related TEAE | Any Severe TEAE | Any Serious TEAE | Any Serious Drug-related TEAE | Any TEAE Leading to Drug Interruption | Any TEAE Leading to Drug Withdrawal | Any TEAE Leading to Death | |
Apremilast/Apremilast | 71 | 36 | 7 | 6 | 2 | 13 | 7 | 0 |
Etanercept/Apremilast | 54 | 15 | 7 | 4 | 1 | 7 | 2 | 0 |
Placebo/Apremilast | 45 | 23 | 4 | 5 | 2 | 8 | 3 | 0 |
A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug for participants who discontinued early. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, clinically significant adverse change in frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. (NCT01690299)
Timeframe: Week 0 to Week 16; mean duration of exposure was 14.90 weeks for placebo group, 15.13 weeks for apremilast group and 15.87 weeks for Etanercept group
Intervention | participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Any TEAE | Any Drug-related TEAE | Any Severe TEAE | Any Serious TEAE | Any Serious Drug-related TEAE | Any TEAE Leading to Drug Interruption | Any TEAE Leading to Drug Withdrawal | Any TEAE Leading to Death | |
Apremilast Plus Placebo Injection | 59 | 27 | 3 | 3 | 2 | 9 | 3 | 0 |
Etanercept Plus Placebo Tablets | 44 | 21 | 3 | 2 | 1 | 3 | 2 | 0 |
Placebo | 45 | 17 | 2 | 0 | 0 | 1 | 2 | 0 |
Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy. (NCT01690299)
Timeframe: Week 0 to Week 16; Placebo controlled phase
Intervention | participants (Number) | ||
---|---|---|---|
Any psoriasis flare captured as a TEAE | Any psoriasis rebound captured as a TEAE | Those with PASI ≥125% baseline score and D/C APR | |
Apremilast Plus Placebo Injection | 1 | 0 | 0 |
Etanercept Plus Placebo Tablets | 0 | 0 | 0 |
Placebo | 3 | 0 | 1 |
Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy. PASI ≥125% of baseline score at any visit after the last dose date for those who discontinued within the phase. (NCT01690299)
Timeframe: From the first dose of apremilast (either Week 0 or Week 16 for participants originally randomized to placebo or etanercept who were switched at Week 16) until 28 days after the last dose of apremilast.
Intervention | participants (Number) | ||
---|---|---|---|
Any psoriasis flare captured as a TEAE | Any psoriasis rebound captured as a TEAE | Those with PASI ≥125% baseline score and D/C APR | |
Apremilast/Apremilast | 4 | 2 | 0 |
Etanercept/Apremilast | 0 | 7 | 1 |
Placebo/Apremilast | 1 | 1 | 0 |
Overall survival was measured from treatment initiation to death, censored at the date patients were last known to be alive for those who had not died. (NCT00378105)
Timeframe: Survival rate at 18 months
Intervention | Percentage of participants (Number) |
---|---|
All Patients | 97 |
"PD from European Bone Marrow Transplant (EBMT) Response Criteria Required one or more:~>25% increased in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation, or >25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation), or >25% increased in plasma cells in a bone marrow aspirate or biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.~Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).~Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).~PFS was measured from treatment initiation to progression or death, censored at the date patients were last known to be alive and disease free" (NCT00378105)
Timeframe: PFS rate at 18 months
Intervention | Percentage of participants (Number) |
---|---|
All Patients | 75 |
Overall Response (OR) was defined as partial response (PR) or better. Response was assessed according to European Group for Blood and Marrow Transplant criteria, modified to include nCR and VGPR, from the International Uniform Response Criteria. (NCT00378105)
Timeframe: Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.
Intervention | percentage of participants (Number) |
---|---|
Phase 1 Population | 100 |
Phase II Population | 100 |
Total | 100 |
Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died. (NCT00378105)
Timeframe: Response rate at 18 months
Intervention | Percentage of participants (Number) |
---|---|
All Patients | 68 |
6 reviews available for thalidomide and Ache
Article | Year |
---|---|
Multiple myeloma, painful neuropathy, acupuncture?
Topics: Acupuncture Therapy; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Mye | 2009 |
[Novel potential uses of thalidomide in the management of pain? A review of the literature].
Topics: Analgesics; Aspirin; Caffeine; Drug Therapy, Combination; Humans; Pain; Phenacetin; Thalidomide | 2003 |
[Thalidomide--new prospective therapy in oncology].
Topics: Analgesics; Angiogenesis Inhibitors; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Huma | 2003 |
Does thalidomide have an analgesic effect? Current status and future directions.
Topics: Animals; Humans; Neuroimmunomodulation; Pain; Thalidomide | 2007 |
Topical and systemic therapy for recurrent aphthous stomatitis.
Topics: Adjuvants, Immunologic; Administration, Topical; Adrenal Cortex Hormones; Analgesics; Anti-Inflammat | 1997 |
Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief.
Topics: Amides; Analgesics; Animals; Antitussive Agents; Azepines; Carisoprodol; Cats; Chickens; Codeine; Co | 1969 |
11 trials available for thalidomide and Ache
Article | Year |
---|---|
A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis.
Topics: Double-Blind Method; Humans; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide | 2022 |
Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Topics: Behcet Syndrome; Humans; Oral Ulcer; Pain; Quality of Life; Thalidomide | 2022 |
Effectiveness and safety of Glycyrrhizae Decoction for Purging Stomach-Fire in Behcet disease patients: Study protocol for a randomized controlled and double-blinding trail.
Topics: Behcet Syndrome; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; D | 2018 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2013 |
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Middle Aged; Pain; Pain Measur | 2016 |
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Double-Blind Method; Etanercept; Female; H | 2017 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biom | 2006 |
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2002 |
23 other studies available for thalidomide and Ache
Article | Year |
---|---|
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Ear; Edema; Female; Freund's Adjuvant; Hyd | 2010 |
Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Line; Cyclooxygenase Inhibitors; Drug Design; Fe | 2012 |
Health-related quality of life after 50 years in individuals with thalidomide embryopathy: Evidence from a German cross-sectional survey.
Topics: Cross-Sectional Studies; Female; Fetal Diseases; Humans; Male; Pain; Quality of Life; Thalidomide | 2022 |
Quality of life and pain in patients with thalidomide embryopathy in Japan.
Topics: Abnormalities, Drug-Induced; Adaptation, Psychological; Adult; Aged; Female; Humans; Japan; Male; Ma | 2020 |
Oxidative stress mediates thalidomide-induced pain by targeting peripheral TRPA1 and central TRPV4.
Topics: Animals; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Pain; Rats; Rats, Sprague-D | 2020 |
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Body Surface Area; Comorb | 2018 |
A Dramatic Case of Odynophagia.
Topics: Aged; Humans; Immunosuppressive Agents; Male; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide | 2018 |
Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Animals; Anti-Inflammatory Ag | 2018 |
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; | 2018 |
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Topics: Aged; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Hematologic | 2015 |
Thalidomide represses inflammatory response and reduces radiculopathic pain by inhibiting IRAK-1 and NF-κB/p38/JNK signaling.
Topics: Animals; Cells, Cultured; Humans; Inflammation; Interleukin-1 Receptor-Associated Kinases; Male; MAP | 2016 |
Thalidomide attenuates the development and expression of antinociceptive tolerance to μ-opioid agonist morphine through l-arginine-iNOS and nitric oxide pathway.
Topics: Animals; Arginine; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Tolerance; Gene Expressi | 2017 |
Kaposiform hemangioendothelioma in multiple spinal levels without skin changes.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Celecoxib; Chil | 2009 |
Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model.
Topics: Animals; Behavior, Animal; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Injections, Int | 2010 |
What has happened to people affected by thalidomide 50 years on?
Topics: Activities of Daily Living; Adult; Arm; Disabled Persons; Female; Health Status; Humans; Leg; Male; | 2011 |
Analgesia enhancing effect of thalidomide.
Topics: Analgesia; Glutamates; Humans; Pain; Pain Management; Thalidomide | 1960 |
Rib pain and increased cough.
Topics: Biopsy; Cough; Diagnosis, Differential; Humans; Male; Middle Aged; Multiple Myeloma; Nurse Practitio | 2005 |
Thalidomide and sensory neurotoxicity: a neurophysiological study.
Topics: Adult; Angiogenesis Inhibitors; Disability Evaluation; Female; Humans; Lupus Erythematosus, Cutaneou | 2008 |
Analgesic effect of thalidomide on inflammatory pain.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Carrageenan; Edema | 2000 |
A neuroimmune interaction in painful peripheral neuropathy.
Topics: Animals; Constriction, Pathologic; Cyclosporine; Dose-Response Relationship, Drug; Immunosuppressive | 2000 |
[Mouth and pharyngeal hyperalgesic syndromes in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Male; Middle Aged; Mouth Diseases; Pain; | 1990 |
Treatment of refractory rheumatoid arthritis--the thalidomide experience.
Topics: Adult; Aged; Arthritis, Rheumatoid; Edema; Female; Humans; Male; Middle Aged; Pain; Sleep Stages; Th | 1989 |
[Thalidomide in the control of pain in leprotic neuritis].
Topics: Female; Humans; Leprosy; Male; Neuralgia; Neuritis; Pain; Thalidomide | 1966 |